Mogamulizumab is a humanised monoclonal antibody against CCR4 that the Federal Drug Agency approved for the treatment of relapsing and refractory mycosis fungoides and Sézary syndrome, two conditions associated with CTCL [114, 115]. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.